Chelation: A fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications

Diabetes

Volumn 61, Issue 3, 2012, Pages 549-559

  Nagai, Ryoji ^a   Murray, David B ^b   Metz, Thomas O ^c   Baynes, John W ^d  

^a JAPAN WOMEN'S UNIVERSITY   (Japan)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALDOSE REDUCTASE INHIBITOR; ALT 462; ALT 486; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AVE 8048; BENAZEPRIL; BENFOTIAMINE; CARNOSINE; COCARBOXYLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ILEPATRIL; LR 9; NORPHENAZONE; NZ 314; OLMESARTAN; PENICILLAMINE; PYRIDOXAMINE; RAMIPRIL; TEMOCAPRILAT; TENILSETAM; THIAMINE; THIOCTIC ACID; TM 2002; TRC 4149; TRC 4186; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CHELATION; CHELATION THERAPY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG MEGADOSE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; IRON CHELATION; KIDNEY DISEASE; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; STREPTOZOCIN DIABETES; WILSON DISEASE;

ALDEHYDE REDUCTASE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CHELATING AGENTS; DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS;

EID: 84857430527     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1120     Document Type: Review

References (50)

1. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-1152 (Pubitemid 351519698)
2. Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris) 2010;58:214-219
3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412
4. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006;11:646-654
5. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 2006;54:405-419 (Pubitemid 44468299)
6. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232:1629-1632 (Pubitemid 16095602)
7. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003a; 419:31-40 (Pubitemid 37279141)
8. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251-258 (Pubitemid 29301430)
9. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62:1671-1681 (Pubitemid 41176049)
10. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-950, 200221
11. Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 2003;278:42012-42019 (Pubitemid 37310465)
12. Schalkwijk CG, Miyata T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids.20 October 2010 [Epub ahead of print]
13. Buettner GR. Use of ascorbate as test for catalytic metals in simple buffers. Methods Enzymol 1990;186:125-127 (Pubitemid 20279948)
14. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625 (Pubitemid 40770750)
15. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070
16. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 2010; 61:482-488
17. Rahbar S, Figarola JL. Inhibitors and breakers of advanced glycation endproducts (AGEs): a review. Curr Med Chem 2002;2:135-161
18. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003;419:63-79 (Pubitemid 37287559)
19. Figarola JL, Scott S, Loera S, et al. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab Res Rev 2005;21:533-534
20. Figarola JL, Loera S, Weng Y, Shanmugam N, Natarajan R, Rahbar S. LR-90 prevents dyslipidemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 2008;51:882-891
21. Izuhara Y, Nangaku M, Takizawa S, et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 2008;23:497-509 (Pubitemid 351767619)
22. Figarola JL, Shanmugam N, Natarajan R, Rahbar S. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007;56:647-655 (Pubitemid 46348459)
23. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001;276:48967-48972
24. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-2487
25. Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003;419:50-54 (Pubitemid 37272159)
26. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-3282 (Pubitemid 35246974)
27. Liu XP, Pang YJ, Zhu WW, et al. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol 2009;36:287-296
28. Monacelli F, Poggi A, Storace D, et al. Effects of valsartan therapy on protein glycoxidation. Metab 2006;55:1619-1624 (Pubitemid 44830135)
29. Wihler C, Schäfer S, Schmid K, et al. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 2005;48:1645-1653 (Pubitemid 41175519)
30. Izuhara Y, Sada T, Yanagisawa H, et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008;28:1767-1773
31. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003;14:1212-1222 (Pubitemid 36514663)
32. Miyata T, van Ypersele de Strihou C. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering. Nephrol Dial Transplant 2006;21:846-849
33. Vasan S, Zhang X, Zhang X, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275-278 (Pubitemid 26251366)
34. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95:4630-4634
35. Joshi D, Gupta R, Dubey A, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol 2009;54:72-81
36. Chandra KP, Shiwalkar A, Kotecha J, et al. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clin Drug Investig 2009;29:559-575
37. Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans 2007;35:853-856 (Pubitemid 350206381)
38. Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 2003;412:42-46 (Pubitemid 36324363)
39. El-Kabbani O, Ruiz F, Darmanin C, Chung RP. Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 2004;61:750-762 (Pubitemid 38650996)
40. Ou P, Nourooz-Zadeh J, Tritschler HJ, Wolff S. Activation of aldose reductase in rat lens and metal-ion chelation by aldose reductase inhibitors and lipoic acid. Free Radic Res 1996;25:337-346 (Pubitemid 26354245)
41. Nakamura J, Hamada Y, Chaya S, et al. Transition metals and polyol pathway in the development of diabetic neuropathy in rats. Diabetes Metab Res Rev 2002;18:395-402 (Pubitemid 35256596)
42. Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGERAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 2010;9:776-784
43. Zheng Y, Li XK, Wang Y, Cai L. The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. Hemoglobin 2008;32:135-145 (Pubitemid 351264519)
44. Urui-Adams JY, Keen CL. Copper, oxidative stress, and human health. Mol Asp Med 2005;26:268-298 (Pubitemid 41225353)
45. Cooper GJ. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 2011;71:1281-1320
46. Baynes JW, Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diab Res 2009;2009:696378
47. Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. Biochem Biophys Res Commun 2010;393:118-122
48. Thangarajah H, Yao D, Chang EI, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 2009;106:13505-13510
49. Liu Q, Sun L, Tan Y, Wang G, Lin X, Cai L. Role of iron deficiency and overload in the pathogenesis of diabetes and diabetic complications. Curr Med Chem 2009;16:113-129
50. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010;345:91-104